Abstract:Background: Diffuse large B-cell lymphoma (DLBCL) especially affects the older population. Old (≥60 years) and very old age (≥80 years) DLBCL patients often present high-risk molecular alterations, lower tolerability to conventional immunochemotherapy, and poor clinical outcomes. In this scenario, attenuated therapeutic strategies, such as the R-MiniCHOP and R-MiniCHOP of the elderly regimens, have emerged for this particularly fragile population. However, the responses, clinical outcomes, and toxicities of these regimens currently remain poorly understood, mainly because these individuals are not usually included in controlled clinical trials. Methods: This retrospective, observational, and single-center real-world study included 185 DLBCL, NOS patients older than 70 years treated at the largest oncology center in Latin America from 2009 to 2020. We aimed to assess the outcomes, determine survival predictors, and compare responses and toxicities between three different primary therapeutic strategies, including the conventional R-CHOP regimen and the attenuated R-MiniCHOP and R-MiniCHOP of the elderly protocols. Results: The median age at diagnosis was 75 years (70–97 years), and 58.9% were female. Comorbidities were prevalent, including 19.5% with immobility, 28.1% with malnutrition, and 24.8% with polypharmacy. Advanced clinical stage was observed in 72.4%, 48.6% had bulky disease ≥7 cm, 63.2% had B-symptoms, and 67.0% presented intermediate–high/high-risk IPI. With a median follow-up of 6.3 years, the estimated 5-year OS and PFS were 50.2% and 44.6%, respectively. The R-MiniCHOP of the elderly regimen had a lower ORR (p = 0.040); however, patients in this group had higher rates of unfavorable clinical and laboratory findings, including hypoalbuminemia (p = 0.001), IPI ≥ 3 (p = 0.013), and NCCN-IPI ≥ 3 (p = 0.002). Although associated with higher rates of severe neutropenia (p = 0.003), the R-CHOP regimen promoted increased OS (p = 0.003) and PFS (p = 0.005) in comparison to the attenuated protocols. Additionally, age ≥ 75 years, high levels of LDH, B-symptoms, advanced clinical stage (III/IV), neutrophilia, and low lymphocyte/monocyte ratio were identified as poor prognostic factors in this cohort. Conclusions: In this large and real-life Latin American cohort, we demonstrated that patients with DLBCL, NOS older than 70 years still do not have satisfactory clinical outcomes in 2024, with half of cases not reaching 5 years of life expectancy after diagnosis. Although the conventional R-CHOP offers response and survival advantages over attenuated regimens, its myelotoxicity is not negligible. Therefore, the outcomes reported and the prognostic factors here identified may assist clinicians in the appropriate selection of therapeutic strategies adapted to the risk for old and very old DLBCL patients.

What problem does this paper attempt to address?

This paper aims to address the unmet medical needs in the treatment options for elderly patients with diffuse large B - cell lymphoma (DLBCL). Specifically, the study focused on the survival predictors, treatment patterns, and clinical outcomes of DLBCL patients over 70 years old. Since these patients are usually accompanied by multiple comorbidities and have a lower tolerance to standard immunochemotherapy, it is necessary to evaluate the efficacy and toxicity of different treatment regimens to determine the optimal treatment strategy. ### Research Background - **Disease Characteristics**: DLBCL is an aggressive non - Hodgkin lymphoma, especially affecting the elderly population. Elderly patients often have high - risk molecular alterations, poor tolerance to conventional immunochemotherapy, and unfavorable clinical outcomes. - **Treatment Challenges**: For older and poorer - physical - condition patients, the standard R - CHOP regimen may not be applicable, and reduced - dose or alternative treatment regimens, such as R - MiniCHOP and R - MiniCHOP of the elderly, need to be explored. ### Research Objectives - **Evaluate Clinical Outcomes**: Analyze the overall survival rate (OS) and progression - free survival rate (PFS) of DLBCL patients over 70 years old. - **Determine Survival Predictors**: Identify the independent predictors that affect patient prognosis. - **Compare Different Treatment Regimens**: Compare the efficacy and toxicity of the three main treatment regimens, namely R - CHOP, R - MiniCHOP, and R - MiniCHOP of the elderly. ### Main Findings - **Survival Rates**: The median follow - up time was 6.3 years, the 5 - year OS was 50.2%, and the 5 - year PFS was 44.6%. - **Treatment Efficacy**: - The objective response rate (ORR) of the R - MiniCHOP of the elderly regimen was lower (p = 0.040), but these patients themselves had more severe conditions, such as hypoalbuminemia (p = 0.001), IPI score ≥ 3 (p = 0.013), and NCCN - IPI score ≥ 3 (p = 0.002). - Although the R - CHOP regimen led to severe neutropenia (p = 0.003), its OS (p = 0.003) and PFS (p = 0.005) were significantly better than those of the reduced - dose regimens. - **Prognostic Factors**: Factors such as age ≥ 75 years, high lactate dehydrogenase (LDH) level, B symptoms, advanced clinical stage (III/IV), neutrophilia, and decreased lymphocyte/monocyte ratio were associated with poor prognosis. ### Conclusions - **Clinical Significance**: DLBCL patients over 70 years old still face unsatisfactory clinical outcomes in 2024, and half of the patients cannot survive more than 5 years after diagnosis. Although the standard R - CHOP regimen has advantages in terms of efficacy and survival rate, its bone marrow toxicity cannot be ignored. Therefore, the research results and the identified prognostic factors can help clinicians select appropriate treatment strategies for elderly DLBCL patients. Through these studies, the authors hope to provide more evidence for clinicians to better manage the treatment of this special population.

Predictors of Survival, Treatment Modalities, and Clinical Outcomes of Diffuse Large B-Cell Lymphoma in Patients Older Than 70 Years Still an Unmet Medical Need in 2024 Based on Real-World Evidence